Sample Size Determination for Phase II Clinical Trials Based on Bayesian Decision Theory

DOI10.2307/2534014zbMath1058.62656OpenAlexW2314247638WikidataQ47291830 ScholiaQ47291830MaRDI QIDQ4665959

Nigel Stallard

Publication date: 11 April 2005

Published in: Biometrics (Search for Journal in Brave)

Full work available at URL: https://doi.org/10.2307/2534014

zbMATH Keywords

optimal stoppingcost-benefit analysisbackwards inductionmultistage designgroup sequential procedure

Mathematics Subject Classification ID

Applications of statistics to biology and medical sciences; meta analysis (62P10) Bayesian problems; characterization of Bayes procedures (62C10) Sequential statistical design (62L05)

Related Items (10)

Determination of the optimal sample size for a clinical trial accounting for the population size ⋮ Meta-analytic-predictive use of historical variance data for the design and analysis of clinical trials ⋮ Bayesian adaptive two-stage design for determining person-time in Phase II clinical trials with Poisson data ⋮ Bayesian designs with frequentist and Bayesian error rate considerations ⋮ Decision Theoretic Designs for Phase II Clinical Trials with Multiple Outcomes ⋮ A Bayesian Decision Approach for Sample Size Determination in Phase II Trials ⋮ Optimizing sample size in relative bioavailability trials using a Bayesian decision-theoretic framework ⋮ Decision-Theoretic Designs for Pre-Phase II Screening Trials in Oncology ⋮ Decision-Theoretic Designs for Phase II Clinical Trials Allowing for Competing Studies ⋮ Bayesian approach to determine the number of subsequent users of a new treatment

This page was built for publication: Sample Size Determination for Phase II Clinical Trials Based on Bayesian Decision Theory